CRC SC Committee Material

Plenary Meeting in Berlin, Germany

Plenary Meeting on October 3, 2025 | Program

 

Session 1: The European Commission CRC initiative: evidence and recommendations for CRC screening

• Lessons learned from the COLONPREV study / Antoni Castells (Spain)
• Age-ranges and test vs. test recommendations for CRC screening under the European Commission Initiative on Colorectal Cancer / Rodrigo Jover (Spain)

Session 2: International experiences with CRC screening

• Scaling Up CRC Screening in Sweden, automation is essential / Maria Farm (Sweden)
• Colonoscopy-related mortality: results from the first 10 years of the Dutch CRC screening program / Esther Toes (the Netherlands)

Session 3: CRC screening, FIT and beyond

• Systematic review of participation, positivity and yield over time in programmatic FIT-based CRC screening / Uri Ladabaum (USA)
• Is single organ screening over? / Nadir Arber (Israel)    

Session 4: Feasibility of personalized CRC screening 

• Risk-stratified CRC screening: public acceptance and experiences with receiving tailored invitations intervals / Brenda van Stigt (the Netherlands)
• How to further improve the Dutch colorectal cancer screening program? – a model-based cost-effectiveness analysis / Marjolein Greuter (the Netherlands)
• Ongoing randomized trials of personalized cancer screening: consideration about methodology / Kevin Selby (Switzerland)

Expert Working Group Meeting in Berlin, Germany

Plenary Meeting on October 3, 2025 | Program

Session 1A: FIT for Screening 

• Impact of changing the FIT method / Anja de Jong (the Netherlands)
• EVIDENCE project - The effect on mortality and incidence / Johanes Blom (Sweden)

Session 1 B: Inequities in CRC Screening 

• Inclusive cancer screening research: Challenges and strategies in reach and involvement of underserved groups / Mirjam Fransen (the Netherlands)
• Introducing CRC Screening in Sub-Saharan Africa: Building Equity from the Ground Up / Lucy Mwangi (the Netherlands)
• The role of creative visual arts-based approaches to promote uptake of, and reduce inequities in, bowel cancer screening / Joanne Cairns (UK) 
• Co-designing interventions to reduce health inequalities for bowel cancer screening for adults with severe mental illness / Steven Robinson (UK)

Session 2 A: Polyp Detection, Characterization, Resection and AI

• Piecemeal Cold Resection of Serrated Lesions >10mm: Expert Method or Generalist Solution? / David Tate (Belgium) 

Session 2 B: Surveillance after Colorectal Neoplasia

• Long-Term Colorectal Cancer Incidence After Serrated Polyp Removal: A Posthoc Assessment of COLONPREV Data / Joaquín Cubiella (Spain)

Session 3 A: Evaluation of New Tests

• Understanding the rapidly changing global landscape of CRC screening and the varying new test performance metrics: FDA label vs Pivotal Trial / John B Kisiel (USA)
• Assessing cost-effectiveness of blood-based tests: do we have enough information? / Robert E Schoen (USA)
• From Detection to Prevention - Early Evidence from RNA based Screening Test for Precancerous Lesions compared to different FIT cut-offs / Lena Krammes (Germany)

Session 3 B: PCCR & Quality in Colonoscopy 

• PCCRC introduction: What's new since the last WEO meeting / Nick Burr (UK)
• The 3-year PCCRC rate as per the WEO methodology: Systematic review and meta-analysis / Rawen Kader (UK)
• Harm from PCCR / Nick Burr (UK)

 

Plenary Meeting in San Diego, California

Plenary Meeting on May 2, 2025 | Program

 

Session 1: FIT matures and still matters

• Randomized controlled trial of FIT vs. screening colonoscopy (COLONPREV): The results are in – What are the implications? / Antoni Castells (Spain)
• Participation and results through 8 rounds of Catalonya’s FIT-based screening program  / Antoni Castells (Spain)

Session 2: The programmatic perspective: Quality, economics, and the individual history 

• Impact of payment tied to adenomas per colonoscopy in Taiwan / Han Mo Chiu (Taiwan)
• Leveraging quantitative FIT results below a program’s threshold / Aasma Shaukat (USA)
• The SPoCK profile: A concise summary of individual screening history for clinical and research use / Uri Ladabaum (USA)

Session 3: Too young to be getting colorectal cancer 

• Current state of screening among 45–49-year-olds following the 2021 US Preventive Services Task Force guidelines: Utilization and results. / Jeffrey Lee (USA)           

Session 4: Artificial Intelligence to advance colorectal cancer research and practice

• Large Language Models for extracting histopathologic diagnoses of colorectal cancer and dysplasia / Brian Johnson (USA) 
• Large Language Models for ascertaining and assigning polyp surveillanc / Vedant Acharya (USA)  
• Artificial intelligence and Large Language Models (LLM): Overview of opportunities to advance colorectal cancer research and screening in practice / Chiraag Kulkarni (USA)

Expert Working Group Meeting in San Diego, California

EWG Meeting on May 2, 2025 | Program

Session 1A: FIT for Screening 

• Experience in Latin America: A Foundation Co-Leading a Government CRC Screening Program / Emilia Caro (Argentina)
• The cost-effectiveness of ethnicity-based age adjustments in New Zealand's Bowel Cancer Screening Program / Danica van den Berg (the Netherlands)
• Age and sex specific thresholds for FIT Screening /  Matthias Harlass (the Netherlands)

Session 1 B: Inequities in CRC Screening 

• A qualitative study of the decision not to take part in population-based colorectal cancer screening among women from lower socio-economic areas in Ireland / Nicholas Clark (Ireland)
• Influence of comorbidities on colorectal cancer screening invitation and participation in a safety-net hospital / Shohei Burns (USA)
• Impact of Spanish language outreach on multi-target stool DNA test adherence in a Spanish-speaking population in a federally qualified health center / Travelle Ellis (USA)
•  Developing a multilevel intervention to improve follow-up of abnormal FIT results in a safety-net population / Ari Bell-Brown (USA)

Session 2 A: Endoscopy Screening Trial

• Updates from CONFIRM / Douglas Robertson (USA) 
• Updates from SCREESCO trial / Johannes Blom (Sweeden)

Session 2 B: Surveillance after Colorectal Neoplasia

• Precision FIT screening and surveillance for colorectal cancer /  Tony Hsiu-Hsi Chen (Taiwan)
• Fecal occult blood testing as a method for post-polypectomy surveillance and in high-risk populations / Rodrigo Jover (Spain)

Session 3 A: Evaluation of New Tests

• The WEO New Test Evaluation Working Group-Discussion of New Directions and Summary of Completed Special Journal Issue / Robert S Bresalier (USA)
• Incidence of Aerodigestive Cancer After Negative High Quality Follow-up Colonoscopy for  Positive Multi-target stool DNA Tests / Doug W Mahoney (USA)
• Do Multi-Cancer Detection Tests Have a Role in Colon Cancer Screening? / William Grady (USA)

Session 3 B: PCCR & Quality in Colonoscopy 

• Global burden and trends of Post-colonoscopy Colorectal Cancer / James Kang (UK)

Plenary Meeting in Vienna, Austria

Plenary Meeting on October 11, 2024 | Program

 

Session 1: Update from ongoing screening colonoscopy trials

• Update on Swedish SCREESCO trial / Anna Forsberg (Sweden)
• Update on 10-year FIT screening in the Netherlands / Esther Toes – Zoutendijk (the Netherlands)

Session 2: Supporting the implementation of screening programs: case studies and guidelines initiatives

• Roadmap for improvement of the implementation of the screening in Montenegro / Ivana Nikčević Kovačević (Montenegro)
• Implementing a CRC screening program using sex specific positivity cut-off: the Finnish experience / Tytti Sarkaela (Finland)
• Update from European Commission Initiative on Colorectal cancer / Carlo Senore (Italy)

Session 3: Combination of Screening tests

• Tandem talk: Integrated screening approaches in CRC Screening populations: are we ready for an add on gastroscopy?

         Primary colonoscopy screening / Jasmin Zessner-Spitzenberg (Austria)

• FIT positive: straight to colonoscopy or a second test to increase specificity  / Uri Ladabaum (USA)

Expert Working Group Meeting in Vienna, Austria

EWG Meeting on October 11, 2024 | Program

Session 1A: FIT for Screening 

• Update on the International Harmonization of FIT methods / Sally Benton (UK)
• Should FIT be annual or biennial? / Samar Al-Homoud (Saudi Arabia)

Session 2 A: Surveillance after Colorectal Neoplasia

• Surveillance preferences after resection of advanced colonic lesions. A vignette study. / Joaquín Cubiella (Spain)
• Personalized risk estimates of advanced neoplasia development in individuals with a family history of colorectal cancer. / Eddymurphy Akwiwu (the Netherlands)

• Combining colonoscopy with FIT can improve current familial colorectal cancer colonoscopy surveillance – a modelling study / Francine Van Wifferen (the Netherlands)

• Polyp size is associated with colorectal cancer death across histologic polyp subtypes: a retrospective study of a screening colonoscopy registry / Jasmin Zessner-Spitzenberg (Austria)

Session 2 B: Coalition to Reduce Inequities in CRC Screening 

• Barriers to bowel cancer screening among Pakistani immigrants in Norway / Paula Berstad (Norway)
• Is grassroots innovation the answer for targeting bowel screening inequalities? The findings from Lancashire’s “Call for a KIT” intervention” / Yasemin Hirst (UK) 
• Using an arts-based approach to optimise culturally tailored images to promote awareness of colorectal cancer screening / Marek Palace (UK)

Session 3 A: Evaluation of New Tests

• Evaluation of New Tests Working Group: Modeling and Use of Surrogate Endpoints / Uri Ladabaum (USA)

Session 3 B: PCCR & Quality in Colonoscopy

• PCCRC & Quality in Colonoscopy: past, present and discussion of future priorities / Matthew Rutter (UK), Ulrike Haug (Germany)

Plenary Meeting in Washington, DC

Plenary Meeting on May 17, 2024 | Program

Session 1: Personalization based on risk assessment

• Using past screening results to adapt a personalized screening program / Reineer Meester (the Netherlands)
• Risk prediction to prescribe a life-long personalized screening program, including age to start and frequency / Ulrike Peters (USA)

Session 2: Quality Assurance in Screening

• Quality assurance with FIT: from performance to implementation / Graeme Young (Australia)
• Colonoscopy quality: Perspective from outside North America / Masau Sekiguchi (Japan)
• The new WEO EWG on Colonoscopy Quality Assurance: Disseminating best-practices worldwide / Evelien Dekker (the Netherlands)

Session 3: On Human Behavior and Programmatic Perspectives

• Applying Principles of Behavioral Economics to Colorectal Cancer Screening / Shivan Mehta (USA)
• Establishing and scaling up FIT-based screening in Mexico / Martin Lajous (Mexico)

Session 4: Emerging Screening Test

• Novel stool and blood tests – How good can they can get at detecting advanced precancerous lesions? / Wiliam Grady (USA)
• Blood based biomarkers (liquid biopsy) to screen for colorectal neoplasia: Stanford MOSAIC model / Ajitha Mannalithara (USA)
• Cost-effectiveness of blood-based colorectal cancer screening tests / Rosita van den Puttelaar (Netherlands)
• Report from the AGA Consensus Workshop on Liquid Biopsy for Average-risk Colorectal Cancer Screening / David Lieberman (USA) 

Expert Working Group Meeting in Washington, DC

EWG Meeting on May 17, 2024 | Program

Session 1A: FIT for Screening 

• FIT systematic review on use of the residual FIT buffer / Douglas Robertson (USA)
• Should the FIT threshold vary by sex? / Thomas Imperiale (USA)
• Dose-response association between fecal hemoglobin concentration in previous screening round and detection of colorectal neoplasia: a systematic review and meta-analysis / Danica van den Berg (the Netherlands)
• Using FIT to identify individuals with a very low risk of colorectal neoplasia / Graeme Young (Australia)

Session 1B: Surveillance after Colorectal Neoplasia

• Risk stratification for surveillance colonoscopy / Theodore R. Levin (USA)
• FORTE / Robert Schoen (USA)
• COOP / Theodore R. Levin (USA)

Session 2 A: Endoscopy Screening Trials 

• Overview of State of Screening Colonoscopy Trials / Robin Mendelsohn (USA)  
• SCREESCO update  /  Robin Mendelsohn (USA)  

Session 2 B: Coalition to Reduce Inequities in CRC Screening 

• Multilevel Interventions to Improve Colorectal Cancer Screening in an Urban Native American Community: A Pilot Randomized Clinical Trial / Aasma Shaukat (USA)

Session 3 A: Evaluation of New Tests

• Strategies for Evaluating New Non-Invasive Screening Tests: Plans for new publication (Special Issue Digestive Diseases and Sciences) / Robert Bresalier (USA)
• The importance of a flexible positivity threshold – report on the global survey of FIT usage / Graeme Young (Australia)

Session 3 B: PCCR & Quality in Colonoscopy

• Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program / Pieter Wisse (Netherlands)
• Cancer Biology or Ineffective Surveillance? A multicentre retrospective analysis of colitis-associated post-colonoscopy  / Rawen Kader (UK)

Plenary Meeting in Copenhagen, Denmark

Plenary Meeting on October 13, 2023 | Program

Session 1: Insights from ongoing CRC screening programs

• CRC screening pilot in Romania - a presentation of the performance of the program / Mircea Manuc (Romania)

Session 2: Management of screen-detected lesions

• Staging of rectal polyps: is there room for improvement? / Maria Pellise (Spain)

Session 3: Novel CRC screening tests

• The NCI/NIH (USA) initiative on blood based multi-cancer detection (MCD) tests / David Weinberg (USA)
  
• The next generation Cologuard test - will this stimulate its use in Europe? / Kevin Selby (Switzerland)

Session 4 Quality in CRC screening

• Developing uniform global standards for colonoscopy quality: Which, defining threshold values, and how to make practical? / Douglas E. Corley (USA)
• Territorial equity in colonoscopy KPI in a national screening program / Antoni Castells (Spain)
• Implementation of the PSPDR alongside the ADR: a dire necessity or superfluous hassle? /Joep IJspeert (Netherlands)

Expert Working Group Meetings in Copenhagen, Denmark

EWG Meeting on October 13, 2023 | Program

Session 1: FIT for Screening

• An evaluation of personalized benefits and harms of colorectal cancer screening in order to facilitate informed decision making on participation in the CRC screening program / Francine van Wifferen (Netherlands)
• Risk prediction algorithms for CRC screening / Christina Therkildsen (Denmark)

• Declining trend in the participation rate in the FIT-based colorectal cancer screening program in the Netherlands - what about other screening programs? / Esther Toes-Zoutendijk (Netherlands)
• FIT can be used in CRC screening to eliminate current disadvantages for women / Callum Fraser (UK)

Session 2a: PCCRC & Quality in Colonoscopy

• Are ADRs at screening associated with CRC risk and death at 17 years? / Kate Wooldrage (UK)

Session 2b: Coalition to Reduce Inequities in CRC Screening

• Who should be targeted first: background risk of non-participants / Hilliene van de Schootbrugge - Vandermeer (Netherlands)
• How to increase participation in colorectal cancer screening – including among vulnerable citizens / Mette Bach Larsen (Denmark)
  
• London Bowel Cancer Screening Social Marketing Campaign - results of a regional intervention to reduce inequalities / Josephine Ruwende (England)

Session 3a: Surveillance After Colorectal Neoplasia

• Use of molecular markers as predictors of metachronous neoplasia / Rodrigo Jover (Spain)
• FIT for surveillance / Joaquin Cubiella (Spain)

Session 3b: Artificial Intelligence and Polyp Management

• Polyp sizing and pathology for diminutive polyps - Do we still need pathology? / Daniel von Renteln (Canada)

Hybrid Plenary Meeting in Chicago, USA

Plenary Meeting on May 5, 2023 | Program

Session 1: CRC Screening policy update

• English national PCCRC audit data / Roland Valori (UK)
• Real-time capture of the patient-reported experience / Alan Smith (Ireland)
• Support for jurisdictions looking to implement screening, including lessons learned in NZ / Susan Parry (New Zealand), Linda Rabeneck (Canada)

Session 2: NordICC at 10 years: Implications for screening colonoscopy

• NordICC at 10 years: Results, Surprises, and Questions for the Investigators / Uri Ladabaum (USA)

Session 3: The many facecs of FIT

• Beyond Positive vs. Negative: Cumulative fecal Hb level for risk prediction / Carlo Senore (Italy)

Session 4: Emerging tests and precision screening

• The New Test EWG Consensus v2 is done: What’s next and how can we have real-world impact? / Robert Bresalier (USA)
• Shifting from universal to precision screening / Chen-Yang Hsu (Taiwan)

Expert Working Group Meetings in Chicago, USA

EWG Meeting on May 5, 2023 | Program

Session 1: CRC Surveillance after Colorectal neoplasia

• Update on FORTE / Robert Schoen (USA)

Session 2: FIT for screening

• New Zealand Bowel Screening Programme Post Colonoscopy CRC -lessons / Susan Parry (New Zealand)
• Impact of indication for procedure, setting and patient characteristic on colonoscopy colorectal cancer detection in Ontario, Canada / Catherine Dubé (Canada)

Session 3: PCCR & Quality in Colonoscopy

• Post-colonoscopy Colorectal Cancers in a Large Integrated Health Care Center: Tumor Characteristics, Survival, and Risk Factors for Mortality / James Kang (UK)
• Combatting PCCRC – an educational experience / Silvia Sanduleanu (Netherlands)

Session 5: Polyp detection, characterization, resection adn AI

• Update on the WEO consensus statement for complex polypectomy / Yutaka Saito (Japan)
• Small steps, big impact, how AI assisted colonoscopy can help reducing carbon footprint / Heiko Pohl (USA)

Virtual CRC SC Meeting at APDW 2022 in Xi’an, China

CRC SC Meeting on November 17, 2022 | Program

• Third Asia Pacific Consensus Recommendations on Colorectal Cancer Screening

Hybrid Plenary Meeting in Vienna, Austria

Plenary Meeting on October 7, 2022 | Program

Session 1: CRC Screening policy update

• Global CRC incidence and mortality trends / Linda Rabeneck (Canada)
• EU Recommendations on cancer screening / Michael Kaminski (Poland)

Session 2: Risk stratification in CRC screening

• Colonoscopy Prioritization / Revital Kariv (Israel)

Session 3: Participation in CRC screening

• The role of Defensive Information Processing in population-based colorectal cancer screening uptake / Nick Clarke (Ireland)
• Reducing the footprint of CRC screening / Iris Seriese (Netherlands)

Session 4: Screen detected CRC

• CRC: indication for ESD / Yutaka Saito (Japan)
• Screen detected T1 CRC in the Netherlands / Lisa van der Shee (Netherlands)

Expert Working Group Meeting in Vienna, Austria

EWG Meeting on October 7, 2022

FIT for Screening

• Association of Fecal Immunological Test with the risk of gastroesophageal cancer within a population with an intermediate risk for cancer / Zohar Levi (Israel)
• A survey aimed to collect quantitative information about screening activity during the pandemic emergency / Carlo Senore (Italy)

PCCRC & Quality in Colonoscopy

• Molecular pathways in post-colonoscopy versus prevalent colorectal cancers: results from a population-based cohort study / Beatriz Carvalho (Netherlands)

Inequities in CRC Screening

• Colorectal Cancer Screening during Pandemic / Samar Alhomoud (Saudi Arabia)
• Participation during the Covid pandemic / Morten Rasmussen (Denmark)
• Factors associated with participation in the Dutch CRC screening program / Esther Toes-Zoutendijk (Netherlands)

Surveillance after Colorectal Neoplasia

• Post-surgery endoscopy surveillance for colorectal cancer / Giulio Antonelli (Italy)
• Surveillance after endoscopic excision of pT1 malignant polyp. Is that different? / Maria Pellisé & Rodrigo Jover (Spain)

Polyp detection, characterization, resection and AI

• CADe, CADx – how good is it and how good should it be? / Roupen Djinbachian (Canada)
• Beyond AI diagnosis: New evidence of ESD, suggesting a refined management of colorectal neoplasm / Yutaka Saito (Japan)

Hybrid Plenary Meeting in San Diego, USA

Plenary Meeting on May 20, 2022 | Program

Session 1: Early-onset

• Prevalence of colorectal neoplasia in young individuals / GIQuIC: Yield of screening 45–49-year-olds / Parth Trivedi (USA)
• Fight CRC: Integrating Stakeholders with Research Initiatives in Early-onset Colorectal Cancer / Jennifer Kolb, Caitlin Murphy (USA)
• Potential Effects of Lowering Colorectal Cancer Screening Age to 45 Years on Colonoscopy Demand, Case Mix, and Adenoma Detection Rate / Seth Crockett (USA)

Session 2: New tests

• Review on regional variation in microbiome / Mingyang Song (USA)
• Update for the WEO Expert Working Group on New Test Evaluation: Assessing the cost effectiveness of new tests / Uri Ladabaum (USA)

Session 3: Risk-based screening and encouraging uptake

• Risk-based screening versus FIT for detecting advanced neoplasia: A within group comparison in a randomized controlled trial / Tim Kortlever (Netherlands)
• Using Facebook to promote the uptake of colorectal cancer screening / Arlinda Ruco (Canada)
• M-TICS: A study to assess the effectiveness of SMS-based interventions to increase participation in a population-based colorectal cancer screening program / Montse Garcia (Spain)

Session 4: Emerging trends

• Green endoscopy / Heiko Pohl (USA)
• How to measure equity by race and ethnicity and socio-economic status, and what to do about the results. An update along with results from recent letter in NEJM / Chyke Doubeni (USA)
• Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study / David van Toledo (Netherlands)
• Comparing Colorectal Cancer Screening Outcomes in the International Cancer Screening Network (ICSN): A Consortium Proposal / Iris Lansdorp-Vogelaar (Netherlands)

Hybrid Expert Working Group Sessions in San Diego, USA

EWG sessions on May 20, 2022 | Program

Session 1: EWGs Surveillance after Colorectal Neoplasia and Polyp detection, characterization, resection and AI

• Why people at high risk remain at high risk after polyp excision / Samir Gupta (USA)
• EPoS study update / Rodrigo Jover (Spain)
• Incomplete resection, complete resection and polyp recurrence / Roupen Djinbachian (Canada)
• Benefits and limitations of using CADx in colonoscopy: learning from the first comparative clinical trial / Sophie Williams (UK)

Session 2: EWGs FIT for Screening and Evaluation of new tests

• A trial of 50,000 US Veterans who were randomized to colonoscopy vs. FIT / Jason Dominitz (USA)
• Adherence to FIT Screening / Paul Limburg (USA)
• Cost effectiveness of outreach strategy for stool-based CRC screening / Durado Brooks (USA)
• Two-sample Fecal Immunochemical Testing as a Tool to avert Colonoscopy in Symptomatic Patients / Pieter Wisse (Netherlands)
• Progress with consensus process | Uri Ladabaum’s presentation from plenary meeting / Robert Bresalier (USA)

Session 3: Case Studies: Impact of COVID-19

• Impact of COVID Pandemic on FIT-Based CRC Screening Programs in 3 Countries: What Does Modeling Tell Us? / Iris Lansdorp-Vogelaar (Netherlands)
• Impact of COVID Pandemic on CRC Screening Ontario: What Did We Learn? / Jill Tinmouth (Canada)
• Impact of COVID Pandemic on FIT Use, Colonoscopy, and Neoplasia Detection: Lessons from Kaiser Permanente / Theodore Levin (USA)